Core B-Modeling & Experimental Therapeutics Core

核心B(建模和实验治疗核心)-摘要/摘要 基因工程小鼠(GEM)模型仍然是本P01几乎所有方面的核心，并具有 对我们理解小鼠和人类胰腺癌都有很大的贡献。宝石模型， 尤其是那些具有可诱导癌基因的基因，使得(I)能够阐明特定的遗传/途径的作用 肿瘤生物学机制的改变，如自噬和免疫，(I)合作社的解剖 Kras*等遗传元件与p16INK4a、P53、P53等不同抑癌基因的相互作用 Smad4，以及(Iii)不同类型肿瘤细胞间异型相互作用的去卷积 微环境，如癌细胞中的Kras*和免疫细胞中的TGFb。在这次更新中，有两个原因 促使我们建立了这个新的核心。首先，每个模型中使用的模型的极端等位基因复杂性 该项目将受益于专门的尖端工程。按照这些思路，值得注意的是，我们的模型 可能存在多达10个基因突变。核心B的ES-GEM系统是一个强大的平台 将新的等位基因引入现有的含有核心PDAC相关等位基因的多等位基因ES系。其次，几乎所有 目的提出利用GEM模型进行临床前实验性治疗试验。这样的试验将受益于专家 在标准化方案能够比较治疗方案的情况下，与专业人员一起执行 横跨P01。在这里，ES-GEM系统又一次提供了巨大的帮助，因为它能够实现高效的发电 来自一轮或两轮囊胚注射的大量队列，以产生可被征募的易患PDAC的小鼠 变成多臂试验。ES-GEM系统已被证明可以产生具有所有 生殖系模型的特征。此外，这种方法大大减少了相关的时间和成本 有大量的繁殖群体进行治疗实验。

Core B (Modeling & Experimental Therapeutics Core) - Abstract/Summary Genetically engineered mouse (GEM) models remain central to virtually all aspects of this P01 and have contributed significantly to our understanding of both mouse and human pancreatic cancer. GEM models, particularly those with inducible oncogenes, have enabled (i) elucidation of the role of specific genetic/pathway alterations in tumor biological mechanisms such as autophagy and immunity, (i) dissection of cooperative interactions between genetic elements such Kras* and different tumor suppressors such as p16ink4a, p53 and Smad4, and (iii) deconvolution of the heterotypic interactions across different cell types of the tumor microenvironment such as Kras* in cancer cells and TGFb in immune cells. In this renewal, two reasons prompted us to establish this new Core. First, the extreme allelic complexity of the models employed in each Project will benefit from dedicated sophisticated engineering. Along these lines, it is worth noting that our models may harbor as many as ten genetic alterations. Core B’s ES-GEM system serves as a powerful platform to introduce new alleles into existing multi-allelic ES lines harboring core PDAC-relevant alleles. Second, nearly all aims propose preclinical experimental therapeutic trials with GEM models. Such trials will benefit from expert execution with professional staff where standardized protocols would enable comparison of therapeutic regimens across the P01. Here again, the ES-GEM system helps tremendously as it enables highly efficient generation of large cohorts from one or two rounds of blastocyst injection to produce PDAC-prone mice that can be enlisted into multi-arm trials. The ES-GEM system has been proven to generate experimental cohorts with all the characteristics of a germline model. In addition, this approach dramatically reduces time and cost associated with large breeding colonies for therapeutic experiments.